agree gilded.
therapeutic vaccine only may be even better than an antibody response as well.
as long as no one else can generate an antibody vaccine an ongoing market maybe?
that would mean repeat vaccine use for each time a person became reinfected.
meaning many more sales - if it produces a sufficient antibody response their would be no need for repeat sales??
Ann: Admedus announces further data from HSV-2 Trial, page-57
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 681 | $17.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.25 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |